Evidence map›Paper›PMID 30013284›Full record

ArticleIndian journal of microbiology2018

Aloe Emodin Reduces Phthiodiolone Dimycocerosate Potentiating Vancomycin Susceptibility on Mycobacteria.

Céline Rens, Pieter-Jan Ceyssens, Françoise Laval, Philippe Lefèvre, Vanessa Mathys, Mamadou Daffé, Véronique Fontaine

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Céline Rens1Unit of Pharmaceutical Microbiology and Hygiene, Université Libre de Bruxelles (ULB), CP205/2, Boulevard du Triomphe, 1050 Brussels, Belgium.
Pieter-Jan Ceyssens2NRC Mycobacteria and Tuberculosis, Scientific Institute of Public Health, J. Wytsman Street, 14, 1050 Brussels, Belgium.
Françoise LavalDepartment of "Tuberculosis and Infection Biology", Institute of Pharmacology and Structural Biology, University of Toulouse, CNRS, University Paul Sabatier, UMR 5089, 205 Route de Narbonne, BP64182, 31077 Toulouse Cedex 04, France.
Philippe Lefèvre1Unit of Pharmaceutical Microbiology and Hygiene, Université Libre de Bruxelles (ULB), CP205/2, Boulevard du Triomphe, 1050 Brussels, Belgium.
Vanessa Mathys2NRC Mycobacteria and Tuberculosis, Scientific Institute of Public Health, J. Wytsman Street, 14, 1050 Brussels, Belgium.
Mamadou DafféDepartment of "Tuberculosis and Infection Biology", Institute of Pharmacology and Structural Biology, University of Toulouse, CNRS, University Paul Sabatier, UMR 5089, 205 Route de Narbonne, BP64182, 31077 Toulouse Cedex 04, France.
Véronique Fontaine1Unit of Pharmaceutical Microbiology and Hygiene, Université Libre de Bruxelles (ULB), CP205/2, Boulevard du Triomphe, 1050 Brussels, Belgium.ORCID 0000-0001-7588-5462
Université Libre de Bruxelles · BECentre National de la Recherche Scientifique · FRInstitut Scientifique de Santé Publique · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of tuberculosis still represent a major public health issue. The emergence of multi-and extensively-drug resistant (MDR and XDR)

Indexed as

Aloe emodinMDRMycobacterium tuberculosisPDIMVancomycin

Identifiers

PMID30013284
PMCPMC6023814
OpenAlexW2802095889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.